HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Roque Pifarré Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Primack, C. Articles by Pifarré, R. Search for Related Content PubMed PubMed Citation Articles by Primack, C. Articles by Pifarré, R.

Ann Thorac Surg 1996;61:1188-1193
© 1996 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Aprotinin Modulation of Platelet Activation in Patients Undergoing Cardiopulmonary Bypass Operations

Departments of Thoracic and Cardiovascular Surgery and Pathology, Loyola University Medical Center, Maywood, Illinois

Accepted for publication December 13, 1995.

Background. Aprotinin significantly decreases postoperative blood loss, yet its exact mechanism of action remains unproven.

Methods. To study the cytoprotective effect on platelets, we collected blood samples from patients during cardiopulmonary bypass (CPB) operations performed with or without aprotinin. Analysis included whole-blood flow cytometry.

Results. The highest percentages of activated platelets (positive for GMP-140 expression) were bound to leukocytes and erythrocytes in all CPB patients. Platelet-platelet activation did not reveal any marked differences between groups. However, in the platelet-cell bound region, increased ristocetin-stimulated platelet activation was observed from 30 minutes on CPB to 90 minutes after CPB with aprotinin (11.9% ± 5.1% to 33.1% ± 8.6%; p< 0.05), but not without aprotinin (17.5% ± 0.1% to 17.9% ± 2.3%). Platelet autoactivation increased more in the untreated group with time on CPB.

Conclusions. This study demonstrates that in the presence of aprotinin, platelets remain unstimulated during CPB and the von Willebrand GPIb-mediated activatability of platelets is preserved, thus maintaining a viable platelet population. Most important, this study reveals that these mechanisms are more related to platelet-leukocyte than to platelet-platelet interactions.

This article has been cited by other articles:

				Y. Kaminishi, Y. Hiramatsu, Y. Watanabe, Y. Yoshimura, and Y. Sakakibara Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2004; 77(2): 644 - 650. [Abstract] [Full Text] [PDF]

				M. Tanaka, K. Kawahito, H. Adachi, and T. Ino Platelet dysfunction in acute type A aortic dissection evaluated by the laser light-scattering method J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 837 - 841. [Abstract] [Full Text] [PDF]

				G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery Anesth. Analg., February 1, 2002; 94(2): 283 - 289. [Abstract] [Full Text] [PDF]

				R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]

				R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF]

				K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]

				M. Poullis, R. Manning, M. Laffan, D. O. Haskard, K. M. Taylor, and R. C. Landis The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1 J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 370 - 378. [Abstract] [Full Text] [PDF]

				S. A. Kozek-Langenecker, S. F. Mohammad, T. Masaki, C. Kamerath, and A. K. Cheung The Effects of Heparin, Protamine, and Heparinase 1 on Platelets in vitro Using Whole Blood Flow Cytometry Anesth. Analg., April 1, 2000; 90(4): 808 - 812. [Abstract] [Full Text] [PDF]

				S. A. Kozek-Langenecker, S. F. Mohammad, T. Masaki, W. Green, C. Kamerath, and A. K. Cheung The Effects of Aprotinin on Platelets In Vitro Using Whole Blood Flow Cytometry Anesth. Analg., January 1, 2000; 90(1): 12 - 12. [Abstract] [Full Text] [PDF]

				F. Ichinose, S. Uezono, R. Muto, H. Uchida, F. Hatori, K. Terui, Y. Niimi, T. Goto, Y. Nakata, and S. Morita Platelet Hyporeactivity in Young Infants During Cardiopulmonary Bypass Anesth. Analg., February 1, 1999; 88(2): 258 - 258. [Abstract] [Full Text] [PDF]

				K. Kawahito, E. Kobayashi, H. Iwasa, Y. Misawa, and K. Fuse Platelet aggregation during cardiopulmonary bypass evaluated by a laser light-scattering method Ann. Thorac. Surg., January 1, 1999; 67(1): 79 - 84. [Abstract] [Full Text] [PDF]

				A. Weerasinghe and K. M. Taylor The platelet in cardiopulmonary bypass Ann. Thorac. Surg., December 1, 1998; 66(6): 2145 - 2152. [Abstract] [Full Text] [PDF]

				R. Pifarre Use of Aprotinin in the Control of Bleeding During Cardiopulmonary Bypass Surgery: Current Status Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 2 - 6. [Abstract] [PDF]